A number of pharmaceutical firms involve their research and development (R&D) staff in their market research and discussions, a new report has revealed.
Intelligence company Cutting Edge Information has published the results of a study into the transition of new products as they pass out of the hands of developers and into commercialisation.
Allowing R&D teams involvement in the later stages of a product can help smooth the "often problematic" transfer, it claimed.
The report noted that when a product moves to trials, a "shift in ownership" also takes place.
"Researchers that are involved in the product's inception understandably feel a sense of ownership for it and often desire to maintain that ownership during later stages," the Cutting Edge Information report continued.
The company compiles and delivers research on a variety of subjects including pharmaceutical and biotechnology firms.
Its clients include GlaxoSmithKline, Johnson & Johnson and Procter & Gamble.